Literature DB >> 12858197

Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells.

C Götherström1, O Ringdén, M Westgren, C Tammik, K Le Blanc.   

Abstract

Adult mesenchymal stem cells (MSCs) have been suggested to decrease lymphocyte proliferation in vitro. We hypothesised that foetal MSCs (fMSCs) would have an immunosuppressive effect on allograft responses in vitro. Human MSCs were isolated and cultured from first-trimester foetal livers and characterised by flow cytometry. fMSC stained positive for CD29, CD44, CD166, CD105, SH-3 and SH-4, and negative for CD14, CD34 and CD45. When plated on adipogenic, chondrogenic and osteogenic media, fMSC differentiated into the respective cell lineage. Compared to adult MSC (aMSC), the proliferative capacity of fMSC was higher. Mitogen stimulation of PBL was inhibited by fMSC. The greatest inhibition (78%) was seen when 30,000 fMSCs were added to 150,000 lymphocytes stimulated by phytohaemagglutinin. Adult and fMSCs were added to mixed lymphocyte cultures (MLC) containing peripheral blood lymphocytes or foetal liver cells. Unlike aMSC, fMSCs did not inhibit MLC. fMSC could be culture-expanded several million folds with no loss of phenotype characteristics, which makes them ideal for ex vivo expansion. fMSC inhibit lymphocyte proliferation induced by mitogens, but not alloreactivity as measured by MLC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858197     DOI: 10.1038/sj.bmt.1704111

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  48 in total

1.  Characterization of mouse clonal mesenchymal stem cell lines established by subfractionation culturing method.

Authors:  Myung-Shin Jeon; Tac-Ghee Yi; Hyun-Ja Lim; Sun-Hwa Moon; Moon-Hee Lee; Joon-Soon Kang; Chul-Soo Kim; Dae-Hyun Lee; Sun U Song
Journal:  World J Stem Cells       Date:  2011-08-26       Impact factor: 5.326

2.  Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art.

Authors:  Arianna Malgieri; Eugenia Kantzari; Maria Patrizia Patrizi; Stefano Gambardella
Journal:  Int J Clin Exp Med       Date:  2010-09-07

Review 3.  High incidence of contaminating maternal cell overgrowth in human placental mesenchymal stem/stromal cell cultures: a systematic review.

Authors:  Celena F Heazlewood; Helen Sherrell; Jennifer Ryan; Kerry Atkinson; Christine A Wells; Nicholas M Fisk
Journal:  Stem Cells Transl Med       Date:  2014-08-25       Impact factor: 6.940

4.  Fetal liver-derived mesenchymal stem cell engraftment after allogeneic in utero transplantation into rabbits.

Authors:  Rafael Moreno; Itziar Martínez-González; Marta Rosal; Marga Nadal; Jordi Petriz; Eduard Gratacós; Josep M Aran
Journal:  Stem Cells Dev       Date:  2011-06-01       Impact factor: 3.272

5.  Comparative immune-phenotypic and functional characteristics of mesenchymal stromal cells from definitive and transitory hematopoietic organs.

Authors:  M N Kozhevnikova; A S Mikaelyan; V I Starostin
Journal:  Dokl Biol Sci       Date:  2008 Sep-Oct

6.  Recapitulating bone development through engineered mesenchymal condensations and mechanical cues for tissue regeneration.

Authors:  Anna M McDermott; Samuel Herberg; Devon E Mason; Joseph M Collins; Hope B Pearson; James H Dawahare; Rui Tang; Amit N Patwa; Mark W Grinstaff; Daniel J Kelly; Eben Alsberg; Joel D Boerckel
Journal:  Sci Transl Med       Date:  2019-06-05       Impact factor: 17.956

7.  Optimization of culture of mesenchymal stem cells: a comparison of conventional plate and microcarrier cultures.

Authors:  J Chang; H Lei; Q Liu; S Qin; K Ma; S Luo; X Zhang; W Huang; Z Zuo; H Fu; Y Xia
Journal:  Cell Prolif       Date:  2012-10       Impact factor: 6.831

Review 8.  The Advancement of Biomaterials in Regulating Stem Cell Fate.

Authors:  Vun Vun Hiew; Siti Fatimah Binti Simat; Peik Lin Teoh
Journal:  Stem Cell Rev Rep       Date:  2018-02       Impact factor: 5.739

9.  Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially.

Authors:  S Jyothi Prasanna; Divya Gopalakrishnan; Shilpa Rani Shankar; Anoop Babu Vasandan
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

10.  Manufacturing mesenchymal stromal cells for phase I clinical trials.

Authors:  Patrick J Hanley; Zhuyong Mei; Maria da Graca Cabreira-Hansen; Mariola Klis; Wei Li; Yali Zhao; April G Durett; Xingwu Zheng; Yongping Wang; Adrian P Gee; Edwin M Horwitz
Journal:  Cytotherapy       Date:  2013-04       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.